Overview Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study Status: Completed Trial end date: 2010-05-01 Target enrollment: Participant gender: Summary To evaluate the efficacy and safety of anidulafungin in the treatment of systemic fungal infections in intensive care and critical care unit patients. Phase: Phase 3 Details Lead Sponsor: PfizerTreatments: AnidulafunginEchinocandinsFluconazoleVoriconazole